Polymorphisms in the Glucagon-Like Peptide 1 Receptor (GLP-1R) Gene Are Associated with the Risk of Coronary Artery Disease in Chinese Han Patients with Type 2 Diabetes Mellitus: A Case-Control Study
Background. Glucagon-like peptide 1 (GLP-1) bestows protective effects upon the cardiovascular system through direct cardiovascular interactions or by improvements to metabolic function. Both these effects are thought to be at least partly mediated by the GLP-1 receptor (GLP-1R). This case-controlle...
Saved in:
Main Authors: | Xiaowei Ma, Ran Lu, Nan Gu, Xiaowei Wei, Ge Bai, Jianwei Zhang, Ruifen Deng, Nan Feng, Jianping Li, Xiaohui Guo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2018/1054192 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01) -
The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01) -
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
by: Xu He, et al.
Published: (2025-01-01) -
Serum Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) in association with the Risk of Gestational Diabetes: A Prospective Case-Control Study
by: Maryam Mosavat, et al.
Published: (2020-01-01) -
Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)